The ACSL4 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population originating from the MCF-7 human breast adenocarcinoma cell line. This loss-of-function model features targeted disruption of the ACSL4 gene, yielding a heterogeneous pool of cells with impaired ACSL4 enzymatic activity. The polyclonal format circumvents clonal selection biases, providing a more representative spectrum of genetic and functional outcomes following gene disruption compared to clonal knockout lines.
MCF-7 is a well-established human breast adenocarcinoma cell line derived from a pleural effusion. It retains estrogen receptor (ER)-positive status and demonstrates estrogen-dependent growth, serving as a canonical model for hormone-responsive breast cancer research. The line is extensively characterized and widely used in studies of ER signaling, endocrine therapy resistance, and metabolic reprogramming in breast cancer.
ACSL4 (acyl-CoA synthetase long-chain family member 4) catalyzes the ATP-dependent conversion of long-chain polyunsaturated fatty acids (PUFAs) such as arachidonic and adrenic acids into acyl-CoA esters. This reaction is a prerequisite for the incorporation of PUFAs into membrane phospholipids, particularly phosphatidylethanolamines, and is essential for the execution of ferroptosis??a regulated necrotic cell death driven by lipid peroxidation. Transcriptional regulation of ACSL4 is mediated by PPAR?? and SREBP1 in response to lipid accumulation and oxidative stress. ACSL4-generated PUFA-CoA derivatives serve as substrates for phospholipid remodeling enzymes, generating oxidizable phospholipids that propagate lipid peroxidation. In this context, ACSL4 acts as a functional antagonist of the lipid hydroperoxide-reducing enzyme GPX4, forming the p53/ACSL4/GPX4 ferroptosis axis. Furthermore, ACSL4 intersects with the PI3K/AKT/mTOR signaling cascade, which governs de novo lipid synthesis, and the AMPK/ACC pathway, which controls fatty acid oxidation, thereby integrating metabolic and cell death signals.
In the MCF-7 breast cancer context, CRISPR/Cas9-mediated ACSL4 knockout is predicted to severely reduce the activation of long-chain PUFAs and their subsequent incorporation into membrane phospholipids. This depletion of peroxidation-prone phospholipids renders the polyclonal knockout population resistant to ferroptosis induction by agents such as erastin or RSL3. The model enables dissection of ACSL4-dependent lipid signaling in an ER+ background, impacting prostaglandin production, membrane fluidity, and ferroptotic responsiveness. Moreover, the inherent heterogeneity of the polyclonal pool mimics tumor cell diversity, allowing examination of adaptive mechanisms and population-level lipid metabolic shifts.
This ACSL4 knockout product is ideally suited for ferroptosis investigation, lipid metabolism research, and anticancer drug screening. Experimentally, users can validate ACSL4 disruption by Western blotting, assess lipid peroxidation through C11-BODIPY staining or malondialdehyde assays, and monitor ferroptosis sensitivity via cell viability measurements. Complementary analyses include RT-qPCR for ferroptotic markers, fatty acid oxidation assays, and phospholipidomics to characterize lipidomic remodeling. These applications support the discovery of ferroptosis-inducing compounds and the elucidation of resistance mechanisms in breast cancer. For further information, please contact Ascent Research.
